Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
wasabi.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases
Creator
Wong, K
Li, J
Keller, M
Reed, D
Tan, X
Rogers, J
Clements, T
Dirmeier, R
Frey, G
Holland, T
Kimmel, B
Lewis, L
Schoepp, R
Schröder, O
Tozer, E
Woodnutt, G
Source
Medline; PMC
abstract
Using a comprehensive set of discovery and optimization tools, antibodies were produced with the ability to neutralize SARS coronavirus (SARS-CoV) infection in Vero E6 cells and in animal models. These anti-SARS antibodies were discovered using a novel DNA display method, which can identify new antibodies within days. Once neutralizing antibodies were identified, a comprehensive and effective means of converting the mouse sequences to human frameworks was accomplished using HuFR™ (human framework reassembly) technology. The best variant (61G4) from this screen showed a 3.5–4-fold improvement in neutralization of SARS-CoV infection in vitro. Finally, using a complete site-saturation mutagenesis methodology focused on the CDR (complementarity determining regions), a single point mutation (51E7) was identified that improved the 80% plaque reduction neutralization of the virus by greater than 8-fold. These discovery and evolution strategies can be applied to any emerging pathogen or toxin where a causative agent is known.
has issue date
2008-05-13
(
xsd:dateTime
)
bibo:doi
10.1093/protein/gzn027
bibo:pmid
18480090
has license
cc-by-nc
sha1sum (hex)
0f2e41a966ec7d622762dc64ba63009e00a69bd5
schema:url
https://doi.org/10.1093/protein/gzn027
resource representing a document's title
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases
has PubMed Central identifier
PMC2461042
has PubMed identifier
18480090
schema:publication
Protein Eng Des Sel
resource representing a document's body
covid:0f2e41a966ec7d622762dc64ba63009e00a69bd5#body_text
is
schema:about
of
named entity 'DISCOVERY'
named entity 'RAPID'
named entity 'SARS-CoV'
named entity 'cells'
named entity 'discovery'
named entity 'SARS-CoV'
named entity 'ability'
named entity 'DNA'
named entity 'discovery'
covid:arg/0f2e41a966ec7d622762dc64ba63009e00a69bd5
named entity 'REDUCTION'
named entity 'THESE'
named entity 'WHERE'
named entity 'COMPLETE'
named entity 'CAUSATIVE AGENT'
named entity 'IDENTIFY'
named entity 'ANIMAL MODELS'
named entity 'CDR'
named entity 'SCREEN'
named entity 'SARS'
named entity 'CONVERTING'
named entity 'SARS CORONAVIRUS'
named entity 'FOCUSED'
named entity 'DNA'
named entity 'DISPLAY'
named entity 'VERO'
named entity 'SINGLE'
named entity 'TOXIN'
named entity 'VARIANT'
named entity 'STRATEGIES'
named entity 'IMPROVED'
named entity 'DISCOVERY'
named entity 'EMERGING INFECTIOUS DISEASES'
named entity 'THERAPEUTIC ANTIBODIES'
named entity 'OPTIMIZATION'
named entity 'COMPREHENSIVE'
named entity 'USING'
named entity 'EMERGING PATHOGEN'
named entity 'NOVEL'
named entity 'DAYS'
named entity 'BEST'
named entity 'VIRUS'
named entity 'HUMAN'
named entity 'MOUSE'
named entity 'NEUTRALIZING ANTIBODIES'
named entity '3.5'
named entity 'ANTIBODIES'
named entity 'MEANS'
named entity 'CELLS'
named entity '80%'
named entity 'APPLIED'
named entity 'TECHNOLOGY'
named entity 'REGIONS'
named entity 'SET'
named entity 'NEW'
named entity 'SATURATION MUTAGENESIS'
named entity 'KNOWN'
named entity 'EVOLUTION'
named entity 'EFFECTIVE'
named entity 'IN VITRO'
named entity 'TOOLS'
named entity 'METHODOLOGY'
named entity 'FOLD'
named entity 'SARS-COV INFECTION'
named entity 'IMPROVEMENT'
named entity 'SEQUENCES'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 11
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software